NCT03564912 is a Phase 1, PHASE2 clinical trial of Capecitabine Oral Tablet [Xeloda] in Colorectal Cancer, sponsored by Zhejiang University.

Who is sponsoring NCT03564912?

NCT03564912 is sponsored by Zhejiang University.

What drugs are being tested in NCT03564912?

Interventions in NCT03564912: Capecitabine Oral Tablet [Xeloda].

What condition does NCT03564912 study?

NCT03564912 studies Colorectal Cancer.

Is NCT03564912 still recruiting?

NCT03564912 is currently completed. Last updated 25 August 2021.

Last reviewed 2021-08-25 · How we verify

NCT03564912

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prospective Study on the Efficacy and Safety of 2 Week or 3 Week Xelox Regimen for Adjuvant Chemotherapy in CRC

Completed Phase 1, PHASE2 Last updated 25 August 2021

What this trial tests

Phase 1, PHASE2 trial testing Capecitabine Oral Tablet [Xeloda] in Colorectal Cancer in 160 participants. Completed in 24 August 2021.

Timeline

12 August 2018

Primary endpoint
24 August 2021

24 August 2021

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1, PHASE2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	160
Start date	12 August 2018
Primary completion	24 August 2021
Estimated completion	24 August 2021
Sites	1 location across China

Drugs / interventions tested

Capecitabine Oral Tablet [Xeloda]

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

Zhejiang University

Who can join

Eligibility, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study select the diagnosis of postoperative colorectal cancer patients with stage II/III to adjuvant chemotherapy, and received 2 weeks and 3 weeks xelox adjuvant treatment process until disease progression or patients died or lost to follow-up. To analyze the difference in efficacy and safety of xelox in 2 weeks and 3 weeks of postoperative adjuvant therapy for colorectal cancer, so as to find a better postoperative adjuvant treatment model.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Biweekly CAPOX versus triweekly CAPOX in the adjuvant therapy of post-surgery CRC: A randomized controlled trial.
Zhang H, Wang D, Tong Z, Xiang T, et al · · 2025 · PMID 40644418 · DOI 10.1371/journal.pone.0313472
Biweekly CAPOX versus Triweekly CAPOX in the adjuvant therapy of post-surgery CRC: a randomized controlled trial
Zhang H, Wang D, Tong Z, Xiang T, et al · · 2023 · DOI 10.21203/rs.3.rs-2823745/v1

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03564912 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 25 August 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03564912.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing